Concepedia

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni,

The Lancet Oncology · 2020 · 525 citations · 12 references

DOI

Concepts

References

12

Final Version of 2009 AJCC Melanoma Staging and Classification

Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text

, , +17

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +17

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

, , +17

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.5K citations · Full text

, , +17

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · New England Journal of Medicine · 2016 · 1.3K citations · Full text

, , +17